98%
921
2 minutes
20
Previous studies suggested racial difference between young melanomas of Caucasians and non-Caucasians. This study aimed to elucidate characteristics of melanomas in young Asians. We analyzed clinical and histologic characteristics of patients under age 40 diagnosed with cutaneous melanomas including in situs. Survival and subgroup analyses were conducted. Among the 45 patients investigated, the most common anatomical sites of melanomas were lower extremities (22/45, 45.3%) and acral lentiginous type was the most common histological variety (18/45, 40%), of which 12 were subungual type. Lymph node involvement and nodular histologic type were significant prognostic factors. Age subgroup analysis revealed that clinical and histopathologic features of adolescents (15-21 years old [YO]) were distinct from those of young adults (22-39 YO), but similar to children (0-14 YO) who showed amelanotic nodules (p < 0.01) and spitzoid subtypes (p < 0.001). Pediatric melanomas (< 20 YO), showed racial differences based on sex (p < 0.01), an-atomical site (p < 0.001), histologic types (p < 0.001), and lymph node involvement at diagnosis (p < 0.047). Understanding the differences among age groups will help clinicians decide management of melanomas in young Asian patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215740 | PMC |
http://dx.doi.org/10.1038/s41598-025-03553-z | DOI Listing |
Lab Invest
September 2025
Department of Pathology and Laboratory Medicine, University of California, Irvine, CA, USA. Electronic address:
Sinonasal mucosal melanoma (SNMM) is a rare aggressive malignancy of the sinonasal tract. Due to its advanced clinical presentation and frequent late-stage diagnosis, the 5-year survival rate is less than 30%, with an even worse prognosis in patients with distant metastasis (SNMM-M). Therefore, characterizing the molecular landscape of SNMM may provide novel therapeutic targets for SNMM-M.
View Article and Find Full Text PDFPigment Cell Melanoma Res
September 2025
Department of Biomedicine, Aarhus University, Aarhus, Denmark.
Low density lipoprotein receptor-related protein 2 (LRP2) is a 600 kilodalton multi-ligand endocytic membrane receptor expressed in several cell types during fetal development, including neuroepithelial cells, and in select absorptive epithelial cells in the adult. In epithelial cancers, LRP2 expression is associated with a differentiated tumor cell state and better prognosis. In previous work, we found that while LRP2 is not expressed in benign naevi, it is frequently acquired in melanoma.
View Article and Find Full Text PDFAnn Dermatol Venereol
September 2025
Université Grenoble Alpes, Service de dermatologie, Centre Hospitalier Universitaire, Grenoble, France; UGA/Inserm U 1209/CNRS UMR 5309 Joint Research Center, Institute for Advanced Biosciences, 38700 La Tronche, France.
Background: COVID-19 pandemic had a variable impact on the severity of melanomas.
Objective: To assess the role of the COVID-19 pandemic in France on the severity of melanomas at initial diagnosis.
Methods: New melanoma cases recorded in the French RIC-Mel database were included in a retrospective study spanning three timeframes: pre-COVID (01/01/2018 to 03/16/2020), lockdown (03/17/2020 to 10/05/2020), and the COVID pandemic period (hereafter referred to as "COVID") (11/05/2020 to 30/09/2022).
Eur J Med Chem
August 2025
Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, 61519, Minia, Egypt.
Melanoma is one of the deadliest forms of cancer. The disease is incurable for many due to its aggressive, metastatic characteristics and its elevated resistance. Herein, we design and synthesize two series of target compounds oxindole-based (7a-h) and non-oxindole-based (8a-h) benzimidazole.
View Article and Find Full Text PDFJ Clin Pharmacol
September 2025
Clinical Pharmacology, Modeling and Simulation, Amgen Inc., South San Francisco, CA, USA.
Oncolytic viruses are an emerging class of immunotherapies for cancer treatment. Talimogene laherparepvec (T-VEC) is a first-in-class oncolytic virus approved globally for advanced melanoma. Herein, we describe the quantitative clinical pharmacology aspects of T-VEC that supported the development of this unique therapy.
View Article and Find Full Text PDF